This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Browse

IDRA-21

1990s benzothiadiazide ampakine that potently slows AMPA receptor desensitization in vitro and improves memory in animals — but has never been tested in humans, has no GMP supply, and is structural…

Aliases (7)

IDRA21 · 7-chloro-3-methyl-3 · 4-dihydro-2H-1 · 2 · 4-benzothiadiazine 1 · 1-dioxide · IDRA-21

TYPICAL DOSE

1-5 mg oral, single dose, daytime only

PRN (research)

ROUTE

—

CYCLE

—

STORAGE

—

Overview

What is IDRA-21?

IDRA-21 is a research-grade ampakine — a positive allosteric modulator of AMPA glutamate receptors. It has been studied preclinically as a cognitive enhancer with low seizurogenic potential relative to earlier ampakines.

Key Benefits

Enhances long-term potentiation and learning in animal models, improves working memory and attention, more stable than aniracetam-class racetams, and reportedly increases verbal fluency anecdotally in human nootropic users.

Mechanism of Action

Slows AMPA receptor desensitization at the glutamate synapse, prolonging excitatory currents and facilitating long-term potentiation. Indirectly increases BDNF expression and downstream synaptic plasticity.

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

Peptide Interactions

piracetam / aniracetam:

Synergistic

Theoretically additive AMPA modulation. Risk: compounds the seizure-threshold concern. No data.

Cholinergic precursors (alpha-GPC, citicoline):

Synergistic

Plausible — AMPA upregulation creates higher acetylcholine demand. No human data.

Other ampakines or AMPA modulators:

Avoid

Additive seizure risk.

Bupropion, tramadol, high-dose modafinil:

Avoid

Compounds with their own seizure-threshold liability.

Sleep deprivation / fasting:

Avoid

Both lower seizure threshold independently.

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Side Effects & Safety

Common (forum): Headache (especially with high or repeated dosing), mild jitter, occasional GI upset
Less common: Insomnia if dosed late, irritability
Rare-serious: Seizure threshold reduction is the main concern. Type-II ampakines block AMPA desensitization aggressively; cyclothiazide (same class) induces seizure activity in slice models. No human seizure reports for IDRA-21 specifically (because no human use has been documented in literature) but the mechanism and class precedent argue for caution, especially in anyone with prior head injury, sleep deprivation, or a low seizure threshold.
Specific watch periods: N/A — no human safety dataset exists.